Since March 2011, Sally Church has produced video blogs about major medical meetings and scientific congresses she attends. Sally’s next video will be from ESMO 2012 in Vienna.
In advance of ASCO 2012 and the release of the abstracts for the meeting, in her most popular video yet, Sally predicted, “What’s hot at ASCO 2012?”
Some of the new cancer drugs in development that Sally discusses in the video include:
- anti PD-1 immunotherapy BMS 936558;
- afatinib in advanced lung cancer;
- antibody drug conjugate T-DM1 in HER2-positive breast cancer;
- dabrafenib & trametinib in metastatic melanoma;
- enzalutamide (MDV3100)
- abiraterone in advanced prostate cancer.
Earlier this year at the 2012 European Association of Urology (EAU) annual congress in Paris, Sally highlighted some of the news from the meeting, including rumors that the UK price of abiraterone (Zytiga) would be discounted by 40% in order to obtain reimbursement (subsequently confirmed).
At the 2011 San Antonio Breast Cancer Symposium (SABCS), Sally discussed some of the exciting data expected at the meeting.
As part of her “Making a Difference” series on Pharma Strategy Blog, at the September 2011 European Multidisciplinary Cancer Congress (ESMO/ECCO 2011) Sally interviewed Dr Gordon B. Mills MD PhD of the MD Anderson Cancer Center about personalized medicine and cancer drug development strategy:
Last year Sally produced videos about the 2011 Congress of the European Hematology Association (EHA) in London & ASCO 2011 in Chicago:
At the 2011 annual meeting of the American Urological Association (AUA) in Washington DC, Sally focused on prostate cancer new product development and the presentation by Dr Charles Sawyers – Sally’s “Making a Difference” series interview with Dr Sawyers on Pharma Strategy Blog is well worth reading!